Publications by authors named "J A van Ipenburg"
Article Synopsis
- This study investigates the effectiveness and safety of a combination therapy using immune checkpoint inhibitors (ICIs) for certain subgroups of metastatic castration-resistant prostate cancer (mCRPC) patients who show an immunogenic profile.
- The trial involved 69 patients with specific genetic markers and assessed the disease control rate after treatment, aiming to exceed 22%.
- Results showed that 38% of patients achieved disease control beyond 6 months, with the highest success in patients with mismatch repair deficiency, but treatment led to significant side effects in some cases, with 20% permanently discontinuing therapy.
The biopsy Gleason score is an important prognostic marker for prostate cancer patients. It is, however, subject to substantial variability among pathologists. Artificial intelligence (AI)-based algorithms employing deep learning have shown their ability to match pathologists' performance in assigning Gleason scores, with the potential to enhance pathologists' grading accuracy.
View Article and Find Full Text PDFBackground Multiparametric MRI (mpMRI) is effective for detecting prostate cancer (PCa); however, there is a high rate of equivocal Prostate Imaging Reporting and Data System (PI-RADS) 3 lesions and false-positive findings. Purpose To investigate whether fluorine 18 (F) prostate-specific membrane antigen (PSMA) 1007 PET/CT after mpMRI can help detect localized clinically significant PCa (csPCa), particularly for equivocal PI-RADS 3 lesions. Materials and Methods This prospective study included participants with elevated prostate-specific antigen (PSA) levels referred for prostate mpMRI between September 2020 and February 2022.
View Article and Find Full Text PDFArticle Synopsis
- Immune checkpoint inhibitors (ICIs) are effective for some metastatic urothelial cancer (mUC) patients, but only 20-25% see a durable response.
- A study investigated the potential of measuring circulating tumor DNA (ctDNA) levels during treatment to predict responsiveness to ICIs in mUC patients, using a discovery cohort of 40 and a validation cohort of 16.
- Results showed that increases in ctDNA at 3 and 6 weeks were strongly associated with shorter progression-free survival and overall survival, indicating that early ctDNA changes could guide better management of treatment strategies.
Metastatic disease is linked to promoter mutations in conjunctival melanomas (CM). Both promoter and mutations are associated with faulty telomere maintenance. This study aimed to determine the prognostic value of ATRX loss in conjunctival melanocytic lesions.
View Article and Find Full Text PDF